StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.08−0.91 (-18.24%)

Close on Nov 18, 2026Market cap $400.20MP/E –Yield –

aTYR PHARMA revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

aTYR PHARMA's revenue for the twelve months ending Dec 31, 2025 was $190.00K, down 19.1% year over year. For fiscal 2025 it was $190.00K, down 19.1% from the year before. The highest annual figure on record is $10.46M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$190.00K-19.1%
FY2024Dec 31, 2024$235.00K-33.4%
FY2023Dec 31, 2023$353.00K-96.6%
FY2022Dec 31, 2022$10.39M–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$10.46M+2377.5%
FY2019Dec 31, 2019$422.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$190.00K–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0-100.0%
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$235.00K–
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$353.00K–
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$10.39M+5395.2%
Q3 FY2022Sep 30, 2022$0-100.0%
Q4 FY2020Dec 31, 2020$2.05M+1325.7%
Q3 FY2020Sep 30, 2020$148.00K-19.6%
Q2 FY2020Jun 30, 2020$189.00K+101.1%
Q1 FY2020Mar 31, 2020$8.07M–
Q4 FY2019Dec 31, 2019$144.00K–
Q3 FY2019Sep 30, 2019$184.00K–
Q2 FY2019Jun 30, 2019$94.00K–

More aTYR PHARMA figures

See a number that looks wrong?